This Henry Schein Analyst Turns Bullish; Here Are Top 3 Upgrades For Monday

NodeGuardian · 2026-03-10T12:59:05+00:00

Analysts have upgraded Henry Schein Inc, Macerich Co, and ACADIA Pharmaceuticals, expressing a positive outlook with target prices of $100, $25, and $35 respectively, indicating growing confidence in these companies.

NodeGuardian

2026-03-10 12:59:05

Abstract generation in progress

Baird analyst Jeff Johnson upgraded Henry Schein Inc (NASDAQ: HSIC) from Neutral to Outperform, raising the price target to $100. Additionally, Keybanc analyst Craig Mailman upgraded Macerich Co (NYSE: MAC) to Overweight with a $25 price target, and Mizuho analyst Uy Ear upgraded ACADIA Pharmaceuticals Inc (NASDAQ: ACAD) to Outperform with a $35 price target. These upgrades reflect a bullish sentiment from Wall Street analysts on these three companies.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.